Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

Core Insights - Daxor Corporation has received FDA 510(k) clearance for its next-generation Blood Volume Analyzer (BVA), which is expected to meet high demand due to its speed, simplicity, and clinical precision [1][2] - The new BVA device allows for precise fluid management in various clinical conditions, addressing a significant healthcare burden associated with volume derangement [2][4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, focusing on addressing the inability to accurately measure blood volume, which leads to suboptimal care and increased healthcare costs [6][8] - The company has over 50 years of experience and has shipped more than 75,000 tests, collaborating with leading medical institutions to validate the effectiveness of BVA-guided care [5][6] Product Features - The new BVA device is rapid, hand-held, and modular, enabling its use in various clinical settings, including cardiology, nephrology, and emergency medicine [4][7] - It provides critical results three times faster than traditional methods, weighs only 7 lbs, and delivers laboratory-grade diagnostic precision [7] Clinical Impact - Studies indicate that BVA-guided care can significantly reduce one-year mortality in heart failure patients by 86%, decrease hospital stays, and lower readmission rates by 56% [3][5] - The device is particularly beneficial for managing conditions like heart failure, critical care, and sepsis, which collectively affect millions of patients annually [2][3]